In a report released yesterday, Derek Archila from Wells Fargo maintained a Hold rating on C4 Therapeutics (CCCC – Research Report), with a price target of $8.00. Derek Archila has given his Hold ...
C4 Therapeutics has a promising pipeline, including cemsidomide for blood cancer and CFT1946 for solid tumors, but definitive data is still far off. Financially stable with $59.6M in cash and $196M in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results